ArticleInternational journal of cancer2020
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Lydia Bellmann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papercites it